Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Hunting for the perfect shot: Organoid- and AI-based Identification of Oncology Drug-Vaccine Interactions

Project description

How cancer drugs affect vaccine protection

While infectious diseases claimed millions of lives in 2019, the burden is not shared equally. Cancer patients, in particular, remain dangerously exposed. Many cancer therapies do their job well, but they often leave behind a compromised immune landscape where vaccines struggle to take hold. This creates a dangerous gap in protection for the people who need it most. The EU-funded OrAIOn project aims to map the hidden intersections between cancer therapy and vaccine failure. Using human tonsil organoids and computational drug profiling, it will assess how hundreds of cancer drugs impact vaccination outcomes. The findings promise tailored vaccines and improved protection for cancer patients worldwide.

Objective

Infectious diseases caused >2 million deaths in 2019 (pre-COVID-19). Cancer patients die more often from infections than healthy individuals and are less effectively protected by vaccines. Several studies link oncology drugs to altered vaccine responses. While designed to inhibit tumor progression, these drugs also affect immune functions and thus may interfere with vaccine responses – for better or worse. A systematic analysis of this problem has so far been hampered by a lack of suitable models and the low throughput of clinical trials. Currently, it is unknown how most oncology drugs, routinely administered to patients, affect vaccine responses. In OrAIOn, I will fill this knowledge gap and systematically survey how a wide range of oncology drugs impact vaccination outcomes. To this end, I will use two high-throughput (HT) approaches: 1) a human tonsil lymphoid organoid-based screen with a custom library of >400 oncology drugs; 2) a computational screen with >20,000 publicly available drug profiles. To predict the impact of multiple drug combinations on vaccination, I will exploit a recent AI model. Finally, I will use in vitro and in vivo models, patient records, and public human datasets to determine and validate the underlying mechanisms. OrAIOn’s groundbreaking outcome will be the first comprehensive database of validated drug-vaccine interactions with detailed mechanistic insights. I will go beyond the state of the art by pioneering tonsil-based HT screens and yielding >3000 single-cell RNA-seq profiles from perturbed lymphoid tissue cells. My insights will inform follow-up clinical trials, leading to better vaccine recommendations and tailored vaccines. They will also improve anti-cancer vaccine strategies. In the long term, OrAIOn will enable me to realize my vision to provide personalized vaccination strategies to all cancer patients.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Net EU contribution
€ 1 499 863,00
Address
GESCHWISTER-SCHOLL-PLATZ
72074 Tuebingen
Germany
Region
Baden-Württemberg Tübingen Tübingen, Landkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 863,00

Beneficiaries (1)